Voyager Therapeutics appoints Alfred Sandrock as President and CEO, effective March 22, 2022

Voyager Therapeutics, Inc.

Alfred Sandrock, former Biogen EVP of R&D, appointed President and CEO effective March 22, 2022.
Sandrock receives base salary of $600,000, signing bonus of $50,000, target annual bonus of 55% of base salary.
Equity grants: stock option for 940,600 shares and RSU for 100,000 shares, both vesting over four years.
Michael Higgins ceases as Interim CEO, remains Chairman and independent director; receives $30,000 transition retainer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alfred Sandrock

President and Chief Executive Officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2022-03-22
Filed: March 22, 2022, 7:59 PM ET

Appointment of Alfred Sandrock, M.D., Ph.D. as President and Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alfred Sandrock was appointed as President and Chief Executive Officer at Voyager Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

Appointment of Alfred Sandrock, M.D., Ph.D. as President and Chief Executive Officer

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-036307

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.